
hospital.vallhebron.com
Oct 10, 2024, 14:07
Ensuring vital access to DFMO for Children with Neuroblastoma
DFMO (difluoromethylornithine) is an experimental drug that has shown promise in treating neuroblastoma, a childhood cancer. It functions by inhibiting the enzyme ornithine decarboxylase, which plays a crucial role in cell growth. By blocking this enzyme, DFMO may help slow down or stop the proliferation of cancer cells.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 19, 2024, 07:24
Dec 19, 2024, 07:21
Dec 19, 2024, 07:20
Dec 19, 2024, 07:17
Dec 19, 2024, 02:52
Dec 19, 2024, 02:47
Dec 19, 2024, 02:43